Brain fog and other long COVID symptoms are the focus of new small treatment studies

WASHINGTON — The Nationwide Institutes of Well being is starting a handful of research to check attainable remedies for lengthy COVID, an anxiously awaited step in U.S. efforts towards the mysterious situation that afflicts hundreds of thousands.

Monday’s announcement from the NIH’s $1.15 billion RECOVER challenge comes amid frustration from sufferers who’ve struggled for months and even years with sometimes-disabling well being issues — with no confirmed remedies and solely a smattering of rigorous research to check potential ones.

“This can be a 12 months or two late and smaller in scope than one would hope however however it’s a step in the appropriate route,” stated Dr. Ziyad Al-Aly of Washington College in St. Louis, who isn’t concerned with NIH’s challenge however whose personal analysis highlighted lengthy COVID’s toll. Getting solutions is important, he added, as a result of “there’s lots of people on the market exploiting sufferers’ vulnerability” with unproven therapies.

Scientists don’t but know what causes lengthy COVID, the catchall time period for about 200 extensively various signs. Between 10% and 30% of persons are estimated to have skilled some type of lengthy COVID after recovering from a coronavirus an infection, a threat that has dropped considerably since early within the pandemic.

“If I get 10 individuals, I get 10 solutions of what lengthy COVID actually is,” U.S. Well being and Human Companies Secretary Xavier Becerra stated.

That’s why thus far the RECOVER initiative has tracked 24,000 sufferers in observational research to assist outline the commonest and burdensome signs — findings that now are shaping multipronged remedy trials. The primary two will have a look at:

— Whether or not taking as much as 25 days of Pfizer’s antiviral drug Paxlovid may ease lengthy COVID, due to a idea that some reside coronavirus, or its remnants, could conceal within the physique and set off the dysfunction. Usually Paxlovid is used when individuals first get COVID-19 and for simply 5 days.

— Therapies for “mind fog” and different cognitive issues. They embody Posit Science Corp.’s BrainHQ cognitive coaching program, one other referred to as PASC-Cognitive Restoration by New York Metropolis’s Mount Sinai Well being System, and a Soterix Medical gadget that electrically stimulates mind circuits.

Two further research will open within the coming months. One will take a look at remedies for sleep issues. The opposite will goal issues with the autonomic nervous system — which controls unconscious capabilities like respiratory and heartbeat — together with the dysfunction referred to as POTS.

A extra controversial examine of train intolerance and fatigue is also deliberate, with NIH looking for enter from some affected person teams nervous that train could do extra hurt than good for sure lengthy COVID victims.

The trials are enrolling 300 to 900 grownup members for now however have the potential to develop. Not like typical experiments that take a look at one remedy at a time, these extra versatile “platform research” will let NIH add further potential therapies on a rolling foundation.

“We are able to quickly pivot,” Dr. Amy Patterson with the NIH defined. A failing remedy could be dropped with out ending the whole trial and “if one thing promising comes on the horizon, we will plug it in.”